Prebiotics with probiotics versus prebiotics · people undergoing liver transplantation
2 findings from 1 review
All‐cause mortality · high‐risk surgical patients with acute calculous cholecystitis.
It is very uncertain whether intervention changes mortality compared with control (very low certainty).
1 finding from 1 review
Serious adverse events · high‐risk surgical patients with acute calculous cholecystitis.
It is very uncertain whether intervention changes serious adverse events compared with control (very low certainty).
1 finding from 1 review
Mortality ‐ Antibiotics versus no antibiotics · patients undergoing liver resections
1 finding from 1 review
Mortality ‐ Long duration antibiotics versus short duration antibiotics · patients undergoing liver resections
1 finding from 1 review
Mortality ‐ Prebiotics and probiotics versus none · patients undergoing liver resections
1 finding from 1 review
Mortality ‐ Pre‐operative and post‐operative prebiotics and probiotics versus post‐operative prebiotics and probiotics · patients undergoing liver resections
1 finding from 1 review
Mortality ‐ Topical povidone iodine gel versus no topical povidone iodine gel · patients undergoing liver resections
It is very uncertain whether intervention changes mortality ‐ Topical povidone iodine gel versus no topical povidone… compared with comparison (very low certainty).
1 finding from 1 review
60‐day mortality ‐ Aprotinin versus control · Patients with liver transplantation.
It is very uncertain whether intervention changes 60‐day mortality ‐ Aprotinin versus control compared with control (very low certainty).
1 finding from 1 review
Thromboembolic episodes ‐ Recombinant factor VIIa (rFVIIa) versus control · Patients with liver transplantation.
It is very uncertain whether intervention changes thromboembolic episodes ‐ Recombinant factor VIIa (rFVIIa) versus… compared with control (very low certainty).
1 finding from 1 review
Serious adverse events ‐ Recombinant factor VIIa (rFVIIa) versus control · Patients with liver transplantation.
It is very uncertain whether intervention changes serious adverse events ‐ Recombinant factor VIIa (rFVIIa) versus… compared with control (very low certainty).
1 finding from 1 review
Blood loss ‐ Aprotinin versus control (litre) · Patients with liver transplantation.
1 finding from 1 review
Blood loss ‐ Tranexamic acid versus control (litre) · Patients with liver transplantation.
1 finding from 1 review
Blood loss ‐ Thromboelastography versus control (litre) · Patients with liver transplantation.
1 finding from 1 review
Blood loss ‐ Tranexamic acid versus aprotinin · Patients with liver transplantation.
1 finding from 1 review
Blood transfusion (red cell or whole blood) · Patients with liver transplantation.
5 findings from 1 review
no estimate extracted
8 studies · 375 participants
Very low
no estimate extracted
4 studies · 159 participants
Very low
no estimate extracted
2 studies · 221 participants
Very low
Show 2 more findings
60‐day mortality ‐ Tranexamic acid versus control · Patients with liver transplantation.
It is very uncertain whether intervention changes 60‐day mortality ‐ Tranexamic acid versus control compared with control (very low certainty).
1 finding from 1 review
60‐day mortality ‐ Recombinant factor VIIa (rFVIIa) versus control · Patients with liver transplantation.
It is very uncertain whether intervention changes 60‐day mortality ‐ Recombinant factor VIIa (rFVIIa) versus control compared with control (very low certainty).
1 finding from 1 review
60‐day mortality ‐ Tranexamic acid versus aprotinin · Patients with liver transplantation.
It is very uncertain whether intervention changes 60‐day mortality ‐ Tranexamic acid versus aprotinin compared with control (very low certainty).
1 finding from 1 review
Primary graft non‐function ‐ Aprotinin versus control · Patients with liver transplantation.
It is very uncertain whether intervention changes primary graft non‐function ‐ Aprotinin versus control compared with control (very low certainty).
1 finding from 1 review